Tessa Therapeutics Pte Ltd., of Singapore, reported preclinical data showing TT-16, its combination immunotherapy integrating CAR T-cell therapy and oncolytic adenovirus expressing immunomodulatory molecules, resulted in durable response in various HER2-positive solid tumor models.